Non-biotinylated Human SLAMF7/CRACC/CD319 Protein
Catalog No: SLAMF7-HP001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human SLAMF7/CRACC/CD319 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ser23-Met226 (UniProt accession: Q9NQ25-1).
Product Details
- Molecular Aliases
- CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12
- Protein Length
- Ser23-Met226
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 25.3 kDa. Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human SLAMF7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human SLAMF7 is greater than 95% as determined by SEC-HPLC.
Immobilized Human SLAMF7, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.2ng/ml determined by ELISA.
Background
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response.
References
- Niels W. C. J. van de Donk, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma[J]. Blood, 2016, 127(6):681-695.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.